Royal Fund Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.6M | Buy |
67,521
+4,208
| +7% | +$349K | 0.56% | 54 |
|
|
2025
Q1 | $5.13M | Buy |
63,313
+713
| +1% | +$57.8K | 0.57% | 55 |
|
|
2024
Q4 | $5.64M | Sell |
62,600
-233,886
| -79% | -$21.1M | 0.53% | 53 |
|
|
2024
Q3 | $29.3M | Buy |
296,486
+235,835
| +389% | +$23.3M | 1.75% | 8 |
|
|
2024
Q2 | $5.62M | Buy |
+60,651
| New | +$5.62M | 0.46% | 39 |
|
|
2018
Q1 | – | Sell |
-102
| Closed | -$8K | – | 726 |
|
|
2017
Q4 | $8K | Buy |
+102
| New | +$8K | ﹤0.01% | 417 |
|